ELSEVIER

DRUG DISCOVERY TODAY

May 2009
Volume 14 · Numbers 9/10
pp. 439–532



Cover Story
In this month's Foundation Review, Wolfgang Fecke and co-authors discuss small-molecule screening strategies for Huntington's disease. Huntington's disease is a genetic neurological disorder caused by a mutation in the *huntingtin* gene. The mutant huntingtin protein mediates neuronal decay, which in turn leads to involuntary body movements and dementia. At present, only symptomatic treatments are available for the disease and addressing neurodegeneration is hampered by the small number of validated drug targets. The authors describe alternative drug discovery approaches, such as attempts to target the mutant protein and recently developed assays that were used to find small molecules able to reverse some of the pathogenic mechanisms of Huntington's disease.

REVIEWS

KEYNOTE

446 Non-coding RNAs and new opportunities for the private sector
Fabrício F. Costa

453 Small molecule drug discovery for Huntington's Disease
Wolfgang Fecke, Marco Gianfriddo, Giovanni Gaviraghi, Georg C. Terstappen and Freddy Heitz

GENE TO SCREEN

465 Application of LC/MS to proteomics studies: current status and future prospects
Guodong Chen and Birendra N. Pramanik

472 Schistosomes—proteomics studies for potential novel vaccines and drug targets
Ricardo DeMarco and Sergio Verjovski-Almeida

INFORMATICS

479 A chemogenomic approach to drug discovery: focus on cardiovascular diseases
Montserrat Cases and Jordi Mestres

486 Understanding nuclear receptors using computational methods
Ni Ai, Matthew D. Krasowski, William J. Welsh and Sean Ekins

POST SCREEN

495 Assessing the bioequivalence of biosimilars. The Retacrit® case
H. Schellekens

500 Organometallic compounds in oncology: implications of novel organotins as antitumor agents
Angela Alama, Bruno Tasso, Federica Novelli and Fabio Sparatore

509 The histamine H3 receptor as a therapeutic drug target for CNS disorders
Mark J. Gemkow, Adam J. Davenport, Silke Harich, Bart A. Ellenbroek, Andrea Cesura and David Hallett

516 Medicinal chemistry strategies in follow-on drug discovery
Hongyu Zhao and Zongru Guo

523 TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders
Atul Tiwari and Pranab Maiti